Anavex Life Sciences Corp (AVXL)

[falconer66a]

Well, you don't know. Others of us do.

We don't really know if 3-71 will show more significant benefits in humans than 2-73 does.

Well, your "We" is yourself. You are welcome to that perception, based upon unstated or misunderstood evidence. It's the "mice aren't men" dictum, which runs against the fact that the preliminary, predictive testing of virtually all new drugs starts, when they are available, with transgenic murines (lab rodents).

My "we," I, have read copious amounts of data and research papers showing, for me, conclusively, that Anavex 3-71 will yield "more significant benefits in humans than 2-73 does." Two major factors (but there are more):

First, Anavex 3-71 is a far stronger sigma-1 receptor agonist, by orders of magnitude. Dosages are in micrograms, not milligrams. Next, it facilitates a greater number and diversity of "downstream" homeostatic and therapeutic outcomes in cells. Lastly, because effective dosages are a tiny fraction of those for blarcamesine, Anavex 3-71 will have even fewer and less severe side effects, adverse events.

Of course, in the regulatory process of sequential clinical trials blarcamesine is closer to FDA approval. It will be first onto pharmacy shelves. But soon after, Anavex 3-71 will supplant blarcamesine; for everyone's benefit.